Compare SPNS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPNS | BEAM |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 1992 | 2020 |
| Metric | SPNS | BEAM |
|---|---|---|
| Price | $43.31 | $27.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $31.33 | ★ $48.09 |
| AVG Volume (30 Days) | 397.1K | ★ 2.2M |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $564,331,000.00 | $55,701,000.00 |
| Revenue This Year | $8.80 | N/A |
| Revenue Next Year | $6.98 | $19.01 |
| P/E Ratio | $37.67 | ★ N/A |
| Revenue Growth | ★ 4.71 | N/A |
| 52 Week Low | $23.69 | $13.53 |
| 52 Week High | $43.36 | $35.25 |
| Indicator | SPNS | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 68.47 | 59.48 |
| Support Level | $43.27 | $23.30 |
| Resistance Level | $43.36 | $29.16 |
| Average True Range (ATR) | 0.09 | 1.77 |
| MACD | -0.00 | 0.66 |
| Stochastic Oscillator | 91.12 | 76.97 |
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.